Sarepta Therapeutics/$SRPT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
- Ticker
- $SRPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 835
- Headquarters
- Cambridge, United States
- Website
- www.sarepta.com
SRPT Metrics
BasicAdvanced
$1.9B
-
-$1.32
0.26
-
Price and volume
Market cap
$1.9B
Beta
0.26
52-week high
$24.68
52-week low
$14.68
Average daily volume
3.1M
Financial strength
Current ratio
4.422
Quick ratio
2.44
Long term debt to equity
0.685
Total debt to equity
0.695
Interest coverage (TTM)
-0.87%
Profitability
EBITDA (TTM)
-17.533
Gross margin (TTM)
19.11%
Net profit margin (TTM)
-6.92%
Operating margin (TTM)
-3.15%
Effective tax rate (TTM)
-4.43%
Revenue per employee (TTM)
$2,360,000
Management effectiveness
Return on assets (TTM)
-1.13%
Return on equity (TTM)
-9.48%
Valuation
Price to revenue (TTM)
0.958
Price to book
1.26
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
25.233
Free cash flow yield (TTM)
3.96%
Free cash flow per share (TTM)
0.722
Growth
Revenue change (TTM)
-20.44%
Earnings per share change (TTM)
119.75%
3-year revenue growth (CAGR)
25.31%
10-year revenue growth (CAGR)
108.81%
3-year earnings per share growth (CAGR)
-49.64%
10-year earnings per share growth (CAGR)
-13.09%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Analyst projections of the future price of Sarepta Therapeutics stock.
Bulls say / Bears say
At the World Muscle Society meeting, Sarepta reported that ambulatory patients treated with ELEVIDYS at ages 8–12 had better results across three functional measures over two years than matched external controls. If confirmed with longer follow-up, this could support use in older patients. (Sarepta Therapeutics)
The FDA has accepted applications seeking traditional approval for AMONDYS 45 and VYONDYS 53, giving Sarepta a regulatory catalyst for two established Duchenne treatments. The applications are supported by confirmatory-study and real-world evidence, though approval is still pending. (Nasdaq)
A September settlement resolved patent disputes over key AAVrh74 gene-therapy patents and released Sarepta from specified claims involving ELEVIDYS. This removes a legal overhang, although the company agreed to pay $39 million. (StreetInsider)
ELEVIDYS carries a boxed warning for acute liver injury and liver failure, and the US label no longer covers non-ambulatory patients. These safety concerns limit the eligible market and may weigh on confidence in the therapy. (StockTitan)
The commercial recovery looks slow: second-quarter revenue fell 34% year on year, and management expected second-half ELEVIDYS demand to be below the first half. Sarepta also said it takes about six months to move from enrolment to treatment, delaying any benefit from stronger sign-ups. (Nasdaq, MarketBeat)
Sarepta’s DM1 pipeline faces a tougher backdrop after Novartis’ candidate failed a trial, prompting Sarepta shares to fall. Reuters noted that drug development for DM1 has proved difficult, so Sarepta’s programme remains clinically risky. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
Upcoming events
No upcoming events
SRPT News
AllArticlesVideos
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Business Wire5 days ago
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Business Wire2 weeks ago
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Business Wire2 weeks ago
Funds containing SRPT
AllUSDEURGBP
Fund name | Fund size | $SRPT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.19% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.19% |
iShares Healthcare Innovation£DRDR | £1B | 0.19% |
iShares Ageing Population€AGED | €822M | 0.17% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.